Order results by:
| Issue | Title | |
| Vol 12, No 4 (2019) | Optimization of drug supply for patients with malignant neoplasms in a region of the Russian Federation | Abstract similar documents |
| A. V. Nikitina, F. V. Gorkavenko, Y. S. Saybel, M. V. Avxentyeva, M. S. Sura, D. V. Fedyaev | ||
| "... The aim was to assess the possibility of optimizing the costs of drugs for cancer patients ..." | ||
| Vol 11, No 3 (2018) | What is the role of antineoplastic drug safety in reimbursement decision making? | Abstract similar documents |
| A. S. Kolbin, A. A. Kurylev | ||
| "... Rationale. From 2014 to 2017, the portion of antineoplastic drugs dossiers submitted ..." | ||
| Vol 9, No 1 (2016) | MATHEMATICAL MODEL OF REIMBURSEMENT DECISION MAKING IN RUSSIA. RESULTS OF VIM LIST FOR 2016 | Abstract similar documents |
| A. S. Kolbin, A. V. Prasolov, E. A. Maksimkina, Yu. E. Balykina, Z. M. Golant, Yu. S. Polushin, A. A. Kurylev, I. A. Vilyum | ||
| "... Background: In 2014 we firstly analyzed the formalized system (points and expert opinions) of drug ..." | ||
| Vol 7, No 1 (2014) | PHARMACOEPIDEMIOLOGY: FROM THEORY TO PRACTICE | Abstract similar documents |
| S. A. Rachina, R. S. Kozlov, Yu. A. Belkova | ||
| "... the use of and the effects of drugs in the whole population or in large groups of people in order ..." | ||
| Vol 10, No 1 (2017) | RESTRICTIVE LISTS OF DRUGS: REGULATIONS, FUNCTIONS, SOURCES OF FINANCE, AND GUIDELINES FOR CREATION | Abstract similar documents |
| M. V. Sura | ||
| "... and sources of finance pertaining to the restrictive lists of drugs, which play a substantial role in the drug ..." | ||
| Vol 12, No 2 (2019) | Dynamics of prices and consumption of anticancer drugs in Russia after their generics and biosimilars became available | Abstract similar documents |
| F. V. Gorkavenko, A. V. Nikitina, E. S. Saibel’, M. V. Avksent’eva, M. V. Sura, D. V. Fedyaev | ||
| "... trends in the general picture of drug prices and consumption. In the present study, we analyze ..." | ||
| Vol 7, No 1 (2014) | EVALUATION OF SAFETY OF DRUG THERAPY IN CLINICAL PRACTICE | Abstract similar documents |
| M. N. Kostyleva, Yu. B. Belousov, A. N. Gratsianskaya, S. S. Postnikov | ||
| "... ), account and analysis of the adverse reactions of drugs in post-marketing period are described. The off ..." | ||
| Vol 5, No 1 (2012) | DYNAMICS OF PREFERENTIAL MAINTENANCE OF CITIZENS WITH ANTIHYPERTENSIVE DRUGS AT THE EXPENSE OF THE REGIONAL BUDGET | Abstract similar documents |
| I. I. Lavrentyeva, A. I. Khokhlov, I. N. Kagramanyan, T. A. Gorokhova | ||
| "... released antihypertensive drugs that are caused by decrease in average costof one prescription. ..." | ||
| Vol 9, No 3 (2016) | DRUGS PROVIDED TO BREAST CANCER PATIENTS WITHIN THE STATE PROGRAMS OF DRUG SUPPLY | Abstract similar documents |
| M. V. Avxentyeva, V. I. Bogin, E. V. Derkach, V. V. Omelyanovskiy, M. B. Stenina, A. V. Tarakanov, M. Yu. Frolov | ||
| "... cancer in various regions of the Russian Federation in the framework of state programs of drug provision ..." | ||
| Vol 12, No 4 (2019) | Clinical and economic analysis of drug costs in a general hospital in 2014-2018 | Abstract similar documents |
| A. T. Burbello, A. S. Fedorenko, E. L. Latariya, M. V. Pokladova, K. A. Zagorodnikova | ||
| "... Objectives. To study the structure of drug purchases by a general hospital considering the names ..." | ||
| Vol 7, No 4 (2014) | ROAD MAP FOR DEVELOPMENT OF PRICE REGULATION SYSTEM AND SYSTEM OF DRUG SUPPLY AT THE EXPENSE OF RUSSIAN FEDERATION HEALTHCARE SYSTEM FUNDS | Abstract similar documents |
| M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentieva | ||
| "... study goal is to prepare a road map for development of price regulation system and system of drug ..." | ||
| Vol 9, No 2 (2016) | MANAGEMENT ASPECT OF THE PROBLEM OF NARCOTIC DRUGS USE | Abstract similar documents |
| S. Yu. Soboleva, A. V. Sobolev, I. A. Kaminskaya | ||
| "... The use of narcotic drugs in healthcare system nowadays is characterized by lawful aspects ..." | ||
| Vol 14, No 2 (2021) | Pharmacoepidemiology and pharmacoeconomics of multidrug- and extensively drug-resistant tuberculosis | Abstract similar documents |
| N. Yu. Nikolenko, D. А. Kudlay, N. P. Doktorova | ||
| "... Treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB ..." | ||
| Vol 13, No 2 (2020) | Improvements to the formation of lists of drugs for medical use: analysis of changes in the Government Decree no. 871 | Abstract similar documents |
| V. V. Omelyanovskiy, E. A. Maksimkina, O. I. Ivakhnenko, M. V. Avxentyeva, M. V. Sura, G. R. Khachatryan | ||
| "... development of approaches for complex drug assessment in Russia, also criteria for its evaluation were under ..." | ||
| Vol 7, No 2 (2014) | ANALYSIS OF DRUG PRODUCTS ASSORTMENT ACQUIRABLE BY HEALTHCARE ORGANIZATIONS FOR MEDICAL TREATMENT IN HOSPITAL SETTINGS WAS CONDUCTED | Abstract similar documents |
| M. G. Malaev | ||
| "... analysis of drug products assortment acquirable by healthcare organizations for medical treatment ..." | ||
| Vol 7, No 3 (2014) | ASSESSMENT OF NECESSARY FINANCIAL EXPENSES ON THE DRUG SUPPLY OF THE PATIENTS WITH ORPHAN DISEASES IN THE RUSSIAN FEDERATION | Abstract similar documents |
| M. V. Sura, K. V. Gerasimova, V. V. Omelyanovskiy, M. V. Avksentyeva | ||
| "... the article presents the results of cost calculation on the drug supply of the patients ..." | ||
| Vol 7, No 4 (2014) | АNALYSIS OF PSYCHOTROPIC DRUG CONSUPTION FOR SCHIZOPHRENIA TREATMENT IN DIFFERENT TYPE HOSPITALS | Abstract similar documents |
| P. S. Nosova, O. V. Reshetko | ||
| "... the goal of our research was to carry out an analysis of psychotropic drug utilization used ..." | ||
| Vol 7, No 4 (2014) | APPLICATION OF MULTIPLE-CRITERIA ANALYSIS FOR OPTIMIZATION OF FINANCING OF RARE DISEASES | Abstract similar documents |
| V. V. Omelyanovskiy, V. K. Fedyaeva, O. Yu. Rebrova | ||
| "... financing of rare disease drugs remains a serious problem for both foreign countries and our ..." | ||
| Vol 8, No 2 (2015) | REASONS FOR DIFFICULTY OF THE PHARMACOECONOMIC ANALYSIS FOR ORPHAN DRUGS. WAYS FOR SOLUTIONS | Abstract similar documents |
| Andrey Vladislavovich Pavlysh, Aleksei Sergeevich Kolbin, Roman Andreevich Gapeshin, Stanislav Mikhailovich Malyshev | ||
| "... Orphan drugs are used for treatment of rare life-threatening diseases. There is no universal ..." | ||
| Vol 9, No 2 (2016) | PHARMACOECONOMIC ANALYSIS OF VESOMNI (SOLIFENACIN AND CONTROLLED RELEASE TAMSULOSIN) TREATMENT OF STORAGE SYMPTOMS ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA | Abstract similar documents |
| N. A. Avxentyev, M. Yu. Frolov | ||
| "... The aim of the current study is pharmacoeconomic evaluation of using combined drug Vesomni ..." | ||
| Vol 9, No 2 (2016) | METASTATIC COLORECTAL TREATMENT COSTS OF USING TARGETED DRUGS IN SECOND AND FURTHER LINES THERAPY | Abstract similar documents |
| N. A. Avxentyev, E. V. Derkach, E. A. Pyadushkina, M. D. Ter-Ovanesov | ||
| "... Targeted drugs are recommended for treatment of metastatic colorectal cancer. Second and further ..." | ||
| Vol 9, No 3 (2016) | CLINICAL AND ECONOMIC EVALUATION OF LACOSAMIDE IN PATIENTS WITH PARTIAL EPILEPSY | Abstract similar documents |
| E. A. Pyadushkina, M. Yu. Frolov | ||
| "... of the Russian Federation in three scenarios: Lacosamide as concomitant drug to standard therapy in comparison ..." | ||
| Vol 11, No 1 (2018) | Modeling microbial drug-resistance: from mathematics to pharmacoeconomics | Abstract similar documents |
| Yu. M. Gomon, M. A. Arepyeva, Yu. E. Balykina, A. S. Kolbin, A. A. Kurylev, M. A. Proskurin, S. V. Sidorenko | ||
| "... optimal algorithm for using antimicrobial agents (AMA) that would minimize the evolving drug-resistance ..." | ||
| Vol 11, No 4 (2018) | Treatment of patients with malignant lymphoproliferative diseases in the Russian Federation: analysis of the data from 75 regions | Abstract similar documents |
| G. R. Hachatryan, T. S. Teptsova, V. A. Lemeshko, N. Z. Musina | ||
| "... . Among the malignant LPDs, the highest costs of drug therapy in 2016 pertained to lymphosarcoma ..." | ||
| Vol 12, No 2 (2019) | Health technology assessment and reimbursement of pharmaceuticals in Italy | Abstract similar documents |
| F. V. Gorkavenko, V. V. Omelyanovskiy, T. P. Bezdenezhnykh, G. R. Khachatryan | ||
| Vol 12, No 3 (2019) | Clinical and economic analysis as an instrument for harmonizing import substitution in the preferential segment of medicinal support | Abstract similar documents |
| E. V. Eliseeva , E. S. Maneeva , R. K. Goncharova , A. V. Kropotov | ||
| "... the qualitative and quantitative indicators of drug supply. Materials and methods. We used the official ..." | ||
| Vol 12, No 4 (2019) | The health technology assessment system in Australia | Abstract similar documents |
| V. V. Omelyanovskiy, E. S. Saybel, T. P. Bezdenezhnykh, G. R. Khachatryan | ||
| "... by the federal budget. The drug evaluation process includes five stages: a review of general information about ..." | ||
| Vol 14, No 2 (2021) | Organizational and economic aspects of triplet therapy of relapsed/refractory multiple myeloma in the Russian healthcare setting | Abstract similar documents |
| E. A. Pyadushkina, E. V. Derkach, V. I. Ignatyeva, E. E. Yagnenkova, T. Yu. Klitochenko, T. V. Shelekhova, A. N. Levanov | ||
| "... Background. The introduction of innovative drugs has significantly increased the treatment ..." | ||
| Vol 14, No 2 (2021) | Analysis of the availability and affordability of pharmaceuticals for children in need of palliative care | Abstract similar documents |
| D. M. Medvedeva, I. A. Narkevich, O. D. Nemyatykh | ||
| "... high scores of over-the-counter drugs (LDI>60%). Conclusions. The results call for better ..." | ||
| Vol 14, No 3 (2021) | Peculiarities of administration of medications to patients with circulatory system diseases within the framework of the federal program of preferential provision of medicines | Abstract similar documents |
| I. K. Petrukhina, R. I. Yagudina, N. V. Veyner, T. K. Ryazanova, E. P. Gladunova, V. A. Kurkin, P. R. Blinkova, E. N. Zaitseva | ||
| Vol 7, No 4 (2014) | IS RUSSIA READY FOR THE INTRODUCTION OF THE NATIONAL REFERENCE PRICING SYSTEM? | Abstract similar documents |
| V. V. Omelyanovskiy | ||
| "... the analysis of foreign pricing and drug supply public funding systems (or a so-called drug ..." | ||
| Vol 9, No 1 (2016) | PHARMACOECONOMIC EVALUATION OF RUFINAMIDE USE FOR THE LENNOX-GASTAUT SYNDROME TREATMENT | Abstract similar documents |
| N. K. Mazina, P. V. Mazin, Yu. V. Kislitsin, E. M. Markova | ||
| "... to evaluate the efficacy of the drug in this pathology, a systematic review of publications of the results ..." | ||
| Vol 10, No 3 (2017) | The strategies of drug supply for patients with chronic hepatitis C | Abstract similar documents |
| E. V. Kornilova, A. D. Ermolaeva, M. G. Rusanova, D. A. Andreev, M. V. Davydovskaya, T. N. Ermolaeva, A. g Pokatilo, K. I. Polyakova, V. A. Dubovtseva, K. А. Kokushkin, A. V. Devyatkin | ||
| "... The report reviews the options of drug supply for patients with chronic hepatitis C in the Russian ..." | ||
| Vol 8, No 1 (2015) | PAYMENT OF NEW EXPENSIVE TECHNOLOGIES IN HEALTH CARE ON THE BASIS OF RISKS -SHARING AGREEMENTS: POSSIBILITIES OF APPLICATION IN THE RUSSIAN FEDERATION | Abstract similar documents |
| L. S. Melnikova | ||
| "... are used in foreign countries at reimbursement of costs for public drug supply. The author estimates ..." | ||
| Vol 8, No 2 (2015) | PRINCIPLES OF IMPORT SUBSTITUTION REGARDING DRUGS | Abstract similar documents |
| Alana Viktorovna Dzaneva, Vitalii Vladimirovich Omel'yanovskii, Saniyat Aleksandrovna Kagermazova | ||
| "... This articles is devoted to major principles of import substitution regarding drugs within ..." | ||
| Vol 10, No 4 (2017) | THE INTERNATIONAL PRACTICE OF DRUG SUPPLY IN THE OUTPATIENT SEGMENT | Abstract similar documents |
| D. V. Lukyantseva, L. S. Mel’nikova, A. P. Tatarinov | ||
| "... The paper examines the international experience of drug supply and the risks faced by countries ..." | ||
| Vol 11, No 2 (2018) | Pharmacoeconomic analysis of treatment with nilotinib as the second line therapy in patients with chronic myeloid leukemia | Abstract similar documents |
| N. A. Avxentyev, M. Yu. Frolov, A. S. Makarov | ||
| "... are registered in second-line, however only dasatinib is included in the government drug reimbursement program ..." | ||
| Vol 14, No 1 (2021) | Development of a method for the analysis of the lists of medicines and its application for the analysis of the lists of medicines in Russia, England, and Italy | Abstract similar documents |
| V. A. Lemeshko, K. I. Matrenin, V. V. Omelyanovskiy, Yu. V. Vasilyeva, G. R. Khachatryan, L. A. Kolganov | ||
| "... and Italy exceeds the total number of drugs included in the list of vital essential and desirable (VED ..." | ||
| Vol 14, No 2 (2021) | Medical care payment improvement within diagnosis-related groups of patients with severe asthma requiring biologic disease-modifying drugs by regional adaptation mechanism in the Moscow Region | Abstract similar documents |
| A. D. Ermolaeva, V. S. Krysanova, T. N. Ermolaeva, K. I. Polyakova, K. A. Kokushkin | ||
| "... drugs (bDMDs) within the constraints of diagnosis-related groups (DRGs) on the level of the Moscow ..." | ||
| Vol 14, No 2 (2021) | Chemoreactome screening of pharmaceutical effects on SARS-CoV-2 and human virome to help decide on drug-based COVID-19 therapy | Abstract similar documents |
| I. Yu. Torshin, O. A. Gromova, A. G. Chuchalin, Yu. I. Zhuravlev | ||
| "... Background. So-called rational drug design is suboptimal when it comes to finding effective ..." | ||
| Vol 13, No 2 (2020) | Affordability of in vivo gene therapy. Problems and potential solutions | Abstract similar documents |
| V. V. Omelyanovskiy, N. Z. Musina, V. A. Lemeshko, A. A. Antonov, F. V. Gorkavenko | ||
| "... Aim. To review foreign approaches to the evaluation and financing of in vivo gene therapy drugs ..." | ||
| Vol 13, No 3 (2020) | Comparative analysis of antipsychotic drug consumption for inpatient schizophrenia treatment: a retrospective study with 5-year follow-up | Abstract similar documents |
| L. B. Vaskova, M. V. Tiapkina, E. V. Mikhaylenko | ||
| "... of antipsychotic drugs (APD) used for inpatient treatment for schizophrenia. Materials and methods ..." | ||
| Vol 13, No 4 (2020) | Acute issues in the pharmacotherapy of hand osteoarthritis | Abstract similar documents |
| O. A. Gromova, I. Yu. Torshin, A. V. Naumov, L. V. Vasilyeva, Ye. F. Yevstratova, А. N. Gromov | ||
| "... osteoarthritis (HO). Apart from non-steroid antiinflammatory drugs (NSAID), promising therapeutic means of HO ..." | ||
| Vol 13, No 4 (2020) | Pharmacoeconomic analysis of first-choice antimicrobial drugs prescribed for outpatient treatment of non-severe community-acquired pneumonia | Abstract similar documents |
| V. G. Deriushkin, A. P. Ternavskii, S. V. Gatsura | ||
| "... The study aimed to perform a pharmacoeconomic analysis of antimicrobial drugs (AMDs) prescribed ..." | ||
| Vol 14, No 3 (2021) | The concept of syndromic diagnoses of osteoarthritis and back pain as a cause of therapy failure | Abstract similar documents |
| M. V. Putilina, N. V. Teplova, O. S. Gerasimova | ||
| "... directly related to pro-inflammatory cytokines and oxidative stress, which makes drug therapy ineffective ..." | ||
| Vol 10, No 1 (2017) | PHARMACOECONOMIC ANALYSIS OF BRENTUXIMAB VEDOTIN THERAPY IN RELAPSED OR REFRACTORY CD30+ SYSTEMIC ANAPLASTIC LARGE CELL LYMPHOMA IN PATIENTS OVER 18 YEARS OF AGE: HEALTH BUDGET IMPACT ANALYSIS | Abstract similar documents |
| A. S. Kolbin, I. A. Vilum, М. A. Proskurin, Yu. E. Balykina | ||
| "... that the introduction of brentuximab vetodin in the List of vital and essential drugs and the Program of state ..." | ||
| Vol 11, No 3 (2018) | The concept of multi-criteria analysis of decision-making in the current system of health technology assessment in Russia | Abstract similar documents |
| V. V. Omelyanovsky, V. K. Fedyaeva, N. Z. Musina | ||
| Vol 12, No 1 (2019) | Evaluation of the clinical efficacy of anti-asthma pharmacotherapy in children using the software package based on the Fishburn method | Abstract similar documents |
| O. V. Zhukova, I. V. Nikiforova | ||
| "... for the distribution of drugs by levels of clinical efficacy” is presented. Conclusion. It has been shown ..." | ||
| Vol 13, No 3 (2020) | The use of various genetically engineered biological drugs and selective immunosuppressants within the current provider-payment model of russian diagnosis-related groups | Abstract similar documents |
| E. V. Derkach, E. A. Pyadushkina, M. V. Avxentyeva, T. V. Boyarskaya, E. E. Yagnenkova, A. S. Mokrova, M. M. Maryanyan | ||
| "... of the range of genetically-engineered biological drugs (GEBD) and the development of new indications ..." | ||
| Vol 14, No 1 (2021) | Clinical and economic constituents of the application of dexamethasone and tocilizumab in the therapy for severe conditions in patients with COVID-19 | Abstract similar documents |
| O. V. Zhukova, A. L. Khokhlov | ||
| "... of severe conditions in patients with COVID-19. A statistical evaluation of the influence of these drugs ..." | ||
| 1 - 50 of 50 Items | ||
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
